Sign up
Pharma Capital

Ergomed PSR acquisition seen as a “good fit”

Numis rates Ergomed a 'buy' with a 280p target price
deal, business men handshake
Ergomed agreed to acquire PSR Group in September

Numis analyst Stefan Hamill says Ergomed PLC’s (LON:ERGO) new acquisition is a “good fit” as the broker upgraded its target price to 280p and repeated  its ‘buy’ recommendation.

In late September, Ergomed announced a €5.7mln deal to acquire Dutch-based PSR Group BV, a niche contract research organisation specialising (CRO) in orphan drug development. Alongside the deal it launched a placing to raise £2.9mln, before expenses.

READ: Ergomed unveils €5.7mln acquisition of Dutch-based PSR Group, part-funded by £2.9mln placing

“Ergomed's acquisition of PSR is a good fit with its existing CRO business, adding an orphan drug-focused CRO that strengthens its capabilities and critical mass in this attractive market niche, as well as its first Benelux-based office in Amsterdam, expanding its geographic footprint in a city that is a front runner to become the future home of the EMA post-Brexit,” Hamill said.

The analyst added: “We upgrade our revenues c.10% over our forecasts, as detailed in the following pages, with EBITDA rising c.6% and EPS rising c.1-2% on the higher share count.”

Jamie_55a91591db06b.jpg
Why Invest In Ergomed Plc? Read More Here

Register here to be notified of future ERGO Company articles
View full ERGO profile

Ergomed Plc Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.